

# Double Trouble: Understanding Sex Differences in Synthetic Lethal interactions in Human Cancers

Alexander Turco

May 30, 2023

# Synthetic Lethality has Been Around for Some Time

- ▶ (1922) American geneticist Calvin Bridges was crossing fruit flies (*Drosophila melanogaster*) and observed certain genes were lethal only in combination
- ▶ (1946) Years later, a colleague of Bridges observed the same phenomena in a different species of fruit fly, *Drosophila pseudoobscura*, and coined the term 'synthetic lethality'

**Synthetic = Combining**

---

<sup>1</sup> Nijman, 2011

# The Combined Inactivation of Two Genes Can Lead to Synthetic Lethal Interactions

- ▶ Synthetic lethal interactions describe the relationship between two genes whose coupled inactivation, but not their individual inactivation, causes cell death or reduces cell viability



- ▶ Inactivation: Preventing or disabling normal function of a gene (e.g. mutation)

# Researchers Harness Synthetic Lethal Interactions in a Variety of Biological Applications

*To gain insight into gene function*

- ▶ In *Saccharomyces cerevisiae* (baker's yeast), the mapping of synthetic lethal interactions has reached a genome-wide scale and these networks of interaction are a rich source for the functional annotation of genes

# Researchers Harness Synthetic Lethal Interactions in a Variety of Biological Applications

## *To gain insight into gene function*


- ▶ In *Saccharomyces cerevisiae* (baker's yeast), the mapping of synthetic lethal interactions has reached a genome-wide scale and these networks of interaction are a rich source for the functional annotation of genes

## *To uncover new opportunities for precision oncology*

- ▶ An emerging strategy is to identify potential synthetic lethal interactions between tumor suppressor genes and other genes that can be simultaneously disrupted leading to cancer cell death (e.g. Olaparib was the first drug to work via a synthetic lethal mechanism)

# Four FDA Approved Anti-Cancer Drugs Work via a Synthetic Lethal Mechanism

- ▶ Olaparib, Niraparib, Rucaparib, Talazoparib are Poly [ADP-ribose] polymerase 1/2 (PARP1/2) inhibitors



# Synthetic Lethality can also Help Explain Factors Related to the Tissue-Specificity of Cancer


**Tissue Specificity:** Cancers which manifest in different human tissues have different molecular, phenotypic, and epidemiological characteristics. Some aspects of this phenomena are;

- ① Variation in lifetime cancer risk
- ② Variation in cancer onset age
- ③ Variation in the genes driving the cancer across tissue types

The literature has only reported the **number of lifetime stem cell divisions** and the **abnormal levels of CpG island DNA methylation** to be factors able to explain the variance in lifetime cancer risk across tissues (aside from well known global and cancer-specific factors)

# Quantifying cSL Load in Normal Human Tissue


**cSL Load:** Quantitatively captures the level of cancer synthetic lethal (cSL) gene pair co-inactivation based on gene expression data from normal human tissues






# Tissue cSL Load in Normal Tissues is Negatively Correlated with Lifetime Cancer Risk

**Tissue cSL Load:** Median cSL load value across all samples of each tissue type




# Synthetic Lethality Increases Predictive Power of Models Associated with Tissue Specificity

**B** Predict lifetime cancer risk (cross-validation)



Stem Cell Divisions


**C** Predict lifetime cancer risk (cross-validation)




Methylation

# Where did the Data come From?

A recently published reference set of genome-wide cSLs common to many cancer types was utilized



# Building Pan-Cancer Synthetic Lethality Networks



# There is Variability in Synthetic Lethal Interactions Depending on Cancer Type

**Pan-Cancer Analysis:** Analysis of multiple types of cancer simultaneously, aims to identify commonalities shared across different types

**Cancer-Specific Analysis:** Analysis of individual cancer types to better understand the variation within a specific cancer type

- ▶ Pan-cancer analyses may overlook cancer-specific differences
- ▶ Availability of datasets for all cancer types varies, this may limit statistical power of pan-cancer analyses


# Sex Differences Add an Additional Layer of Complexity

Human sex differences are mainly caused by;

- 1 Gonadal hormone secretions
- 2 Genes located on the sex chromosomes (X and Y)

This leads to differences in the frequency of certain cancer types and the efficacy of treatments in males and females

# Sex Differences Add an Additional Layer of Complexity



# The Objective

Can we build sex-specific synthetic lethality networks for various cancer types?

More specifically, we are trying to elucidate the differences in synthetic lethal interactions between males and females using a network based approach.